FDA gives Teva tentative approval for generic Diovan
JERUSALEM The Food and Drug Administration has granted tentative approval for Teva Pharmaceutical Industries’ generic version of Novartis’ Diovan, Teva announced June 12.
Diovan, known generically as valsartan, is used to treat hypertension. The FDA’s tentative approval covers generic valsartan tablets in doses of 40mg, 80mg, 160mg and 320mg. Teva expects the FDA to grant final approval for the tablets when Novartis’ patent for the drug expires, in September 2012.
Diovan had sales of about $1.5 billion for the 12 months ending March 30, according to IMS data.
ShopKo to open in-store clinics in Wisconsin
MADISON, Wis. Meriter, a provider of healthcare services, has teamed up with ShopKo to open two FastCare clinics in Madison in mid-October.
Meriter’s clinics, which will be located in ShopKo East and ShopKo West, will be staffed by nurse practitioners who can offer treatment for such acute ailments as pink eye, bladder infections and skin rashes. The n.p. can write a prescription, if needed.
“We’re very pleased to provide this service to residents, as well as visitors, to our community,” stated Geoff Priest, Meriter chief medical officer. “Providing quality health care that is convenient, both in hours and location, is very important to us at Meriter.”
Green Bay, Wis.-based Bellin Hospital, in partnership with ShopKo, started the FastCare concept. Since then, they have negotiated partnerships with other health care systems, including ThedaCare in Appleton, Aspirus in Wausau and Olmstead in Rochester, Minn. Others underway include Beaver Dam and one in Waukesha.
Alnylam inks potential $93 million deal with Kyowa Hakko Kogyo
CAMBRIDGE, Mass. Alnylam Pharmaceuticals has signed a collaborative deal with Kyowa Hakko Kogyo, that could be worth as much as $93 million, to develop and market the experimental respiratory drug ALN-RSV01, according to the Associated Press.
ALN-RSV01 is currently in midstage development for respiratory syncytial virus, which can cause severe lower respiratory infections, particularly in infants. Most of Alynlam’s pipeline, though, is still in the preclinical phase of development, with potential candidates for liver cancer, Huntington’s disease, pandemic flu, and cystic fibrosis, among others.
This is the company’s second recent deal. At the end of May, Alnylam signed a research partnership deal with Takeda Pharmaceuticals worth as much as $1 billion.